Revvity, Inc.
95.30-1.15 (-1.19%)
Oct 29, 4:00:02 PM EDT · NYSE · RVTY · USD
Report date
≈ Jan 26, 2026 (in 88 days)EPS
1.12 (1.04 ~ 1.21)Revenue
682.02M (669.79M ~ 693.74M)Key Stats
Market Cap
11.06BP/E (TTM)
49.12Basic EPS (TTM)
1.94Dividend Yield
0%Recent Filings
8-K
Revvity appoints new CAO
Revvity appointed Anita Gonzales as Vice President and Chief Accounting Officer on October 23, 2025, effective immediately. The 49-year-old CPA, who joined as Vice President and Controller in May 2023, brings a decade of experience from General Electric in audit and controllership, plus prior roles at PwC. This internal promotion bolsters financial oversight amid ongoing operations. No compensation details disclosed.
10-Q
Q2 FY2025 results
Revvity posted Q2 revenue of $720.3M, up 4% y/y from $691.7M, with Life Sciences gaining 5% on software strength and Diagnostics edging 3% higher in immunodiagnostics and reproductive health. Gross margin slipped to 54.5% from 55.7%, hit by tariffs and mix shifts, yet operating income climbed 6% y/y to $90.8M on leverage and productivity. Diluted EPS held at $0.46, matching last year, while YTD figures show revenue up 3% to $1.385B and EPS steady at $0.81. Cash dipped to $991.8M after $447.5M in buybacks, but $1.5B revolver capacity cushions liquidity against $3.2B debt. Tariffs sting, but pricing offsets much of it. Solid footing amid headwinds. Buybacks signal confidence.
8-K
Revvity Q2 revenue up 4%
Revvity reported Q2 2025 revenue of $720 million, up 4% reported and 3% organic from last year, with Life Sciences growing 5% and Diagnostics 3%. GAAP EPS from continuing operations hit $0.47, while adjusted EPS dipped to $1.18 amid higher costs; margins slipped slightly to 26.6%. The company raised full-year guidance to $2.84-$2.88 billion in revenue and $4.85-$4.95 adjusted EPS, signaling confidence despite market headwinds. Execution trumps volatility.
10-Q
Q1 FY2025 results
Revvity kicked off fiscal 2025 with revenue climbing 2% year-over-year to $664.8 million for the quarter ended March 30, 2025, fueled by 3% growth in Diagnostics while Life Sciences edged up 1% on software gains offsetting solutions dips. Gross margins expanded 186 basis points to 56.5%, lifting operating income 64% to $72.2 million and diluted EPS from continuing operations 52% to $0.35, reconciled against 120,233 weighted shares with no anti-dilution flags. Cash from operations dipped to $134.1 million, yielding free cash flow of $118.1 million after $16.0 million capex (derived), yet $1.14 billion in cash bolsters liquidity alongside a $1.5 billion revolver through 2030 and $3.17 billion in fixed-rate debt. Share repurchases hit $153.6 million, trimming shares outstanding. Tariffs pose a headwind, potentially trimming operating income by $20 million this year.
8-K
Revvity Q1 beats expectations
Revvity reported Q1 2025 revenue of $665 million, up 2% reported and 4% organically from $650 million a year ago, with adjusted EPS from continuing operations rising to $1.01 from $0.98. Life Sciences revenue grew 1% to $340 million, while Diagnostics surged 3% to $324 million, though its adjusted margin dipped to 22.8% from 24.3%. Strong execution beat expectations. The company reaffirmed 3-5% full-year organic growth and $4.90-$5.00 adjusted EPS guidance amid macroeconomic shifts.
IPO
Website
Employees
Sector
Industry
BDSX
Biodesix, Inc.
6.54-0.01
CRL
Charles River Laboratories Inte
180.15-7.78
DGX
Quest Diagnostics Incorporated
174.78-3.50
ILMN
Illumina, Inc.
95.03-2.77
IQV
IQVIA Holdings, Inc.
217.83-0.30
NOTV
Inotiv, Inc.
1.33-0.01
QDEL
QuidelOrtho Corporation
27.94-0.25
QGEN
Qiagen N.V.
47.19-0.76
TMO
Thermo Fisher Scientific Inc
558.31+0.68
TWST
Twist Bioscience Corporation
32.21-1.36